The 14-3-3eta protein is a marker of synovial inflammation that is released into synovial fluid and peripheral blood in rheumatoid arthritis (RA) and erosive psoriatic arthritis.
- One in five RF and CCP seronegative early stage RA patients is found to be positive for 14-3-3eta protein.
- Patients with active joint RA disease have higher values of 14-3-3eta protein than those with inactive RA or psoriasis without arthritis.
- 14-3-3eta protein has a 93% specificity in patients with RA.
Unlike RF and CCP, 14-3-3eta protein is a therapeutically modifiable marker to monitor response to therapy. A decrease in 14-3-3eta protein in response to DMARDs (disease-modifying antirheumatic drugs) and anti-TNF (tumor necrosis factor) drugs indicates better clinical outcomes; an increase is associated with worse outcomes despite apparent clinical remission.
- Values > or=0.2 ng/mL are elevated and indicative of RA disease or erosive psoriatic arthritis.
- Values >0.50 ng/mL are associated with more aggressive RA disease and poorer outcomes.
$79 per year
$6.60 per month billed annually
$79 per year
Save time on interpreting lab results with the largest database of biomarkers online. In-depth research on any test at your fingertips, all stored and tracked in one place.Learn More